TriLink BioTechnologies collaborates with Johns Hopkins University to establish a new RNA Innovation Center

Rhea-AI Summary

TriLink BioTechnologies, a Maravai LifeSciences company (NASDAQ: MRVI), is collaborating with Johns Hopkins University to establish a new RNA Innovation Center. This partnership aims to accelerate research in RNA therapeutics and discovery by providing funding, technology, and expertise to Hopkins researchers. TriLink's investment includes access to their proprietary RNA synthesis technology, CleanScript™, to advance mRNA development. The collaboration reinforces TriLink's commitment to nucleic acid-based therapies and will contribute to the development of advanced treatments for patients.

Positive

• Establishment of a new RNA Innovation Center in collaboration with Johns Hopkins University.

• Acceleration of research in RNA therapeutics and discovery.

• Investment in funding and technology to lower barriers to RNA innovation.

• Access to TriLink's leading RNA synthesis technology, CleanScript™, for mRNA development.

• Provision of technical expertise and critical supplies to support research and therapeutic development.

• Opportunity for Hopkins researchers to leverage cutting-edge discovery tools for RNA applications.

Negative

• None.

The collaborative center will help to lower barriers to RNA innovation and discovery

SAN DIEGO--(BUSINESS WIRE)-- TriLink BioTechnologies (TriLink®), a Maravai™ LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, is collaborating with the Johns Hopkins University to accelerate transformational research in RNA therapeutics and discovery. A new center within the Johns Hopkins Whiting School of Engineering will accelerate research and therapeutic development, leveraging TriLink’s leading RNA synthesis technology.

TriLink’s investment includes direct funding for the center and access to TriLink’s proprietary in vitro transcription technology, CleanScript™, which will enable Hopkins researchers to advance mRNA development. Additionally, TriLink will provide technical expertise and access to other critical discovery and manufacturing supplies, further lowering the barriers to discovery and application.

“The collaboration with Johns Hopkins reinforces our commitment to advancing nucleic acid-based therapies,” commented Drew Burch, President, Nucleic Acid Products, Maravai LifeSciences. “Our participation in this center of excellence allows TriLink to share its deep knowledge and expertise in nucleic acid production, helping to enable these researchers at Hopkins with the tools they need to develop advanced therapies to treat patients."

According to Ed Schlesinger, dean of the Whiting School of Engineering, the aspiration for this center is the transformation of human health through the development of breakthroughs in RNA applications. Schlesinger adds that the availability of cutting-edge discovery tools will enable Johns Hopkins to grow its RNA research community and increase the cycle of innovation on campus.

Jeff Coller, Bloomberg Distinguished Professor of RNA Biology and Therapeutics and a leader in messenger RNA stability and translation will serve as the inaugural director of the center, which will be anchored in the Institute of NanoBioTechnology (INBT) and open this spring. The center will bring together Johns Hopkins experts in RNA biology, genetic medicine, drug delivery, and biotechnology under one roof, serving as a training center for the next generation of RNA investigators and as a one-university nexus for RNA researchers across the various schools.

About TriLink BioTechnologies

TriLink BioTechnologies, a Maravai LifeSciences company, is a global leader in nucleic acid and mRNA solutions. TriLink delivers unrivaled chemical and biological experience, CDMO services, and high-quality readymade and custom materials, including its patented CleanCap® mRNA capping technology. Pharmaceutical leaders, biotech disruptors, and world governments depend on TriLink to meet their greatest challenges, from delivering the COVID-19 vaccine at warp speed, to empowering innovative treatments in oncology, infectious diseases, cardiology, and neurological disorders, to enabling future pandemic response plans.

For more information, visit trilinkbiotech.com

About Maravai LifeSciences

Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world’s leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.

For more information about Maravai LifeSciences, visit maravai.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20240513577547/en/

Media Contact:

Liz Robinson of CG Life

TriLink BioTechnologies

+1 312-997-2436

lrobinson@cglife.com

Investor Contact:

Deb Hart

Maravai LifeSciences

+ 1 858-988-5917

ir@maravai.com

Source: TriLink BioTechnologies

FAQ

What is the collaboration between TriLink BioTechnologies and Johns Hopkins University about?

TriLink BioTechnologies is collaborating with Johns Hopkins University to establish a new RNA Innovation Center aimed at accelerating research in RNA therapeutics and discovery.

What is TriLink's investment in the collaboration?

TriLink's investment includes direct funding for the center, access to their proprietary in vitro transcription technology, CleanScript™, and provision of technical expertise and critical supplies to support Hopkins researchers.

Who will serve as the inaugural director of the new RNA Innovation Center?

Jeff Coller, Bloomberg Distinguished Professor of RNA Biology and Therapeutics, will serve as the inaugural director of the center.

Where will the new RNA Innovation Center be located?

The center will be anchored in the Institute of NanoBioTechnology (INBT) at Johns Hopkins University and is set to open this spring.

What is the goal of the collaboration between TriLink and Johns Hopkins University?

The goal is to provide Hopkins researchers with the tools, technology, and expertise needed to develop advanced therapies to treat patients.

How will the collaboration contribute to lowering barriers to RNA innovation?

The collaboration will provide access to TriLink's leading RNA synthesis technology, CleanScript™, and other critical supplies, helping to accelerate research and therapeutic development.

What areas of expertise will be brought together under one roof at the new RNA Innovation Center?

The center will bring together Johns Hopkins experts in RNA biology, genetic medicine, drug delivery, and biotechnology to serve as a training center for the next generation of RNA investigators.

What is the role of Jeff Coller in the collaboration with Johns Hopkins University?

Jeff Coller will serve as the inaugural director of the new RNA Innovation Center, anchoring it in the Institute of NanoBioTechnology (INBT) at Johns Hopkins University.

When is the new RNA Innovation Center expected to open?

The center is set to open this spring and will serve as a hub for RNA researchers across various schools at Johns Hopkins University.

Why is the collaboration between TriLink and Johns Hopkins University significant?

The collaboration aims to accelerate transformational research in RNA therapeutics and discovery, contributing to the advancement of nucleic acid-based therapies.

What is the focus of the new RNA Innovation Center at Johns Hopkins University?

The center will focus on advancing breakthroughs in RNA applications and transforming human health through innovative research.

How will the collaboration impact research and therapeutic development at Johns Hopkins University?

The collaboration will provide Hopkins researchers with access to TriLink's proprietary technology, technical expertise, and critical supplies to support the development of advanced therapies.

Who commented on the collaboration with Johns Hopkins University?

Drew Burch, President of Nucleic Acid Products at Maravai LifeSciences, commented on the collaboration, highlighting the commitment to advancing nucleic acid-based therapies.

What is the role of TriLink BioTechnologies in the collaboration?

TriLink will provide direct funding for the center, access to its proprietary technology, CleanScript™, technical expertise, and critical supplies to support research and therapeutic development at Johns Hopkins University.

What are the benefits of the collaboration between TriLink and Johns Hopkins University?

The collaboration will enable Hopkins researchers to leverage cutting-edge discovery tools, advance mRNA development, and grow the RNA research community.

How will the collaboration between TriLink and Johns Hopkins University contribute to lowering barriers to RNA innovation?

The collaboration will provide Hopkins researchers with access to TriLink's leading RNA synthesis technology, CleanScript™, technical expertise, and critical supplies, thus lowering barriers to discovery and application.